A molecular basis for multidrug resistance and reversal of the resistance
Akiyama, S.; Yoshimura, A.; Kikuchi, H.; Kamiwatari, M.; Nagata, Y.; Seto, K.; Sakota, R.; Utsunomiya, A.; Hanada, S.; Hashimoto, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt 2-1): 1266-1272
1989
ISSN/ISBN: 0385-0684 PMID: 2567148 Document Number: 326679
Multidrug-resistance is frequently characterized by enhanced drug efflux resulting from a membrane glycoprotein of 170,000 daltons (P-glycoprotein). Analysis of cloned cDNAs for the human MDR 1 gene, whose product is the P-glycoprotein, indicates that P-glycoprotein is an energy-dependent drug-efflux system for cytotoxic hydrophobic anticancer drugs. We have demonstrated that a photoanalog of a reversing agent, SDB-ethylenediamine, specifically binds to P-glycoprotein. The binding site on P-glycoprotein seems to be identical with that of anticancer agents and other reversing agents. On the other hand, the radioactive photoactive dihydropyridine calcium channel blocker, [3H] azidopine, photolabels P-glycoprotein in membrane vesicles from multidrug-resistant cells. This photolabeling is almost completely inhibited by excess dihydropyridine analogs that reverse or lower drug-resistance. In contrast, the labeling is not significantly inhibited by analogs that do not reverse resistance. These results suggest that it may be possible to quickly screen for dihydropyridine analogs that reverse multidrug resistance by measuring the inhibition of [3H] azidopine labeling of P-glycoprotein.